ArriVent BioPharma, Inc. AVBP Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $37.62M-38.6% | $32.18M+59.6% | $32.17M+60.1% | $27.72M+27.3% | $61.29M+261% | ||
| $8.49M+54.9% | $6.65M+87.7% | $6.15M+48.4% | $5.9M+50.6% | $5.48M+48.2% | ||
| $46.11M-30.9% | $38.82M+63.8% | $38.32M+58.1% | $33.62M+30.8% | $66.77M+223% | ||
| -$46.11M+30.9% | -$38.82M-63.8% | -$38.32M-58.1% | -$33.62M-30.8% | -$66.77M-223% | ||
| -$43.32M+32.7% | -$35.54M-72.3% | -$34.98M-70.1% | -$31.4M-43.5% | -$64.39M-270% | ||
| -$0.96+49.5% | -$0.78-27.9% | -$0.83-36.1% | -$0.90-38.5% | -$1.90-171% | ||
| -$46.67M+30.9% | -$39.58M— | -$39.07M— | -$34.38M— | -$67.53M— | ||
| -$46.11M+30.9% | -$38.82M-63.8% | -$38.32M-58.1% | -$33.62M-30.8% | -$66.77M-223% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is ArriVent BioPharma, Inc. profitable?
- ArriVent BioPharma, Inc. is not currently profitable: it reported a net loss of $145.2M over the trailing twelve months.
- What is ArriVent BioPharma, Inc.'s earnings per share?
- ArriVent BioPharma, Inc.'s diluted EPS over the trailing twelve months is $-3.47.
- Where does ArriVent BioPharma, Inc.'s income statement data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.